Brief: Morphosys AG Says 2024 Financial Guidance Published On January 30, 2024, Cannot Be Maintained And Therefore Was Revoked

Morphosys AG

29/04/2024 21:08

April 29 (Reuters) - MorphoSys AG  MORG.DE :
    * MORPHOSYS' 2024 FINANCIAL GUIDANCE PUBLISHED ON JANUARY
30,
2024, CANNOT BE MAINTAINED AND THEREFORE WAS REVOKED
    * WILL NO LONGER MAKE A FORECAST FOR GROSS MARGIN OR
REVENUES FROM
MONJUVI PRODUCT SALES
    * COST OF SALES IN Q1 OF 2024 AMOUNTED TO EUR 2.8 MILLION
(3M
2023: EUR 1.0 MILLION)
    * FOR 2024, MORPHOSYS EXPECTS RESEARCH AND DEVELOPMENT
EXPENSES OF
EUR 170 MILLION TO EUR 185 MILLION ON A STANDALONE BASIS
    * SHAREHOLDER ACCEPTANCE PERIOD FOR NOVARTIS OFFER HAS
COMMENCED
AND WILL END ON MAY 13, 2024, AT 24:00 HOURS CEST
    * Q1 MONJUVI (TAFASITAMAB-CXIX) U.S. NET PRODUCT SALES OF
US$ 6.4
MILLION
    * PLANS SUBMIT A NEW DRUG APPLICATION FOR PELABRESIB IN
COMBINATION WITH RUXOLITINIB IN MYELOFIBROSIS TO US FDA IN
SECOND HALF OF 2024
    * MORPHOSYS - PLANS TO SUBMIT A MARKETING AUTHORIZATION
APPLICATION FOR PELABRESIB IN COMBINATION WITH RUXOLITINIB IN
MYELOFIBROSIS TO EMA IN H2 2024
    * FOR Q1 2024, CONSOLIDATED NET LOSS WAS EUR 311.0 MILLION
(Q1
2023: CONSOLIDATED NET LOSS OF EUR 32.2 MILLION)

Source text for Eikon:  ID:nBw1S3zz9a 
Further company coverage:  MORG.DE 

 ((Reuters.Briefs@thomsonreuters.com;))